Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
60.46 USD +2.91% Intraday chart for Lantheus Holdings, Inc. +2.16% -2.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing MT
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors CI
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients MT
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients CI
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors CI
Lantheus Names Amanda Morgan Chief Commercial Officer MT
Truist Adjusts Price Target on Lantheus Holdings to $82 From $80, Maintains Buy Rating MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday MT
Lantheus Holdings Q4 Adjusted Earnings, Revenue Climb; Issues Q1, Full Year Guidance; Shares Rise MT
Transcript : Lantheus Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024
(LNTH) LANTHEUS HOLDINGS Forecasts Q1 EPS Range $1.50 - $1.54 MT
(LNTH) LANTHEUS HOLDINGS Forecasts Fiscal Year 2024 EPS Range $6.50 - $6.70 MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 Revenue $354M MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 EPS $1.75 MT
Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Lantheus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lantheus Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Lantheus to Supply Imaging Agent for Alzheimer's Study MT
Lantheus Holdings, Inc. Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging CI
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Lantheus Sued by Novartis Entities for Patent Infringement MT
Sector Update: Health Care Stocks Higher Friday Afternoon MT
Sector Update: Health Care MT
Lantheus Sued by Novartis Entities for Patent Infringement MT
Lantheus Sued by Novartis Entities for Patent Infringement DJ
Chart Lantheus Holdings, Inc.
More charts
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company's products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company's license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
60.46 USD
Average target price
93.67 USD
Spread / Average Target
+54.92%
Consensus
  1. Stock
  2. Equities
  3. Stock Lantheus Holdings, Inc. - Nasdaq
  4. News Lantheus Holdings, Inc.
  5. Lantheus : Credit Suisse Adjusts Lantheus Holdings PT to $14 From $16, Maintains Neutral Rating